Zimberelimab (GLS-010) is a fully human monoclonal antibody of the IgG4 subclass that targets PD-1 with a high affinity, demonstrated by an EC50 of 210 pM. This antibody effectively inhibits the interaction between PD-1 and its ligands PD-L1 and PD-L2, with IC50 values of 580 pM and 670 pM respectively, in CHO-S cell assays. Zimberelimab has been shown to exhibit potent antitumor activities. It is applicable in the research of various cancers, including cervical cancer, non-small cell lung cancer, and classical Hodgkin?€?s lymphoma, making it a valuable tool for oncological studies focused on immune checkpoint pathways.
Zimberelimab (GLS-010) is a fully human monoclonal antibody of the IgG4 subclass that targets PD-1 with a high affinity, demonstrated by an EC50 of 210 pM. This antibody effectively inhibits the interaction between PD-1 and its ligands PD-L1 and PD-L2, with IC50 values of 580 pM and 670 pM respectively, in CHO-S cell assays. Zimberelimab has been shown to exhibit potent antitumor activities. It is applicable in the research of various cancers, including cervical cancer, non-small cell lung cancer, and classical Hodgkin?€?s lymphoma, making it a valuable tool for oncological studies focused on immune checkpoint pathways.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
